X linked agammaglobulinemia: a single centre experience from India

Area of Science:

• Pediatric Immunology
• Genetics
• Clinical Medicine

Background:

• X-linked Agammaglobulinemia (XLA) is a primary immunodeficiency disorder.
• Patients with XLA are susceptible to recurrent bacterial infections.
• Intravenous immunoglobulin (IVIg) therapy is a standard treatment for XLA.

Purpose of the Study:

• To analyze clinical profiles of XLA patients.
• To evaluate the efficacy of IVIg therapy.
• To determine the impact of early diagnosis on complications.

Main Methods:

• Retrospective analysis of seven XLA cases.
• Review of patient data including age, infections, comorbidities, and treatment response.
• Assessment of outcomes following IVIg infusion therapy.

Main Results:

• Patients diagnosed at a mean age of 3.5 years received IVIg (400-600 mg/kg every 3-4 weeks).
• Follow-up averaged 9 years, showing observed complications and response to therapy.
• Early diagnosis correlated with a decrease in infection-related complications.

Conclusions:

• Early diagnosis of XLA is vital for minimizing long-term complications.
• Consistent IVIg therapy is effective in managing XLA.
• Tertiary care centers play a key role in managing primary immunodeficiencies.